Hepion pharmaceuticals announces publication of food effect study with rencofilstat

Edison, n.j., oct. 20, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other fibrotic diseases, today announced that the peer-reviewed journal, clinical pharmacology in drug development, has published the results of a clinical trial examining the effect of food on the oral bioavailability of rencofilstat, the company's lead drug candidate.
HEPA Ratings Summary
HEPA Quant Ranking